Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal
By Adria Calatayud
Sanofi said it agreed to buy vaccine specialist Dynavax Technologies in a $2.2 billion cash deal that seeks to strengthen the French drugmaker's immunization portfolio after it suffered setbacks in clinical trials.
Under the deal, Sanofi will start a tender offer of $15.50 a share in cash to acquire all of Dynavax, which has a hepatitis B shot approved in the U.S. and a candidate for a shingles vaccine under development, the companies said Wednesday.
The deal has been unanimously approved by Dynavax's board, the companies said.
"Dynavax enhances Sanofi's adult immunization presence by adding differentiated vaccines that complement Sanofi's expertise," Sanofi's executive president for vaccines, Thomas Triomphe, said.
For Dynavax, joining Sanofi will help it amplify the impact of its vaccines due to the French company's commercial reach and development capabilities, Dynavax Chief Executive Ryan Spencer said.
Sanofi said it plans to fund the acquisition from existing cash resources and doesn't expect any impact on its 2025 guidance.
The deal is expected to close in the first quarter of 2026, subject to conditions, the companies said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
December 24, 2025 01:55 ET (06:55 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for November
This Once-Hot AI Stock Now Looks Deeply Undervalued
The 10 Best Companies to Invest in Now
3 of the Best Dividend Stocks to Own
United States